Ritter Pharmaceuticals Inc (RTTR)

[Klinsmann]

RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over one billion people worldwide.
RP-G28 effectively stands out as the only therapeutic regimen impacting the natural history of the disease, alleviating the symptoms and reducing the frequency of symptomatic episodes of lactose intolerance. The product stimulates the growth of lactose-metabolizing bacteria in the colon, which reduces lactose-derived gas production, and thereby mitigates the symptoms of lactose intolerance in the process.
The Phase 2b/3 program is underway. Results expected in 2017.

http://www.ritterpharmaceuticals.com/product-platform/rpg28